ADMA Biologics, Inc. (ADMA) is a publicly traded Healthcare sector company. As of July 5, 2026, ADMA trades at $8.95 with a market cap of $2.07B and a P/E ratio of 12.97. ADMA moved +3.95% today. Year to date, ADMA is -51.25%; over the trailing twelve months it is -50.66%. Its 52-week range spans $7.21 to $25.67. Analyst consensus is strong buy with an average price target of $19.67. Rallies surfaces ADMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for ADMA combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $8.95 |
| Market Cap | $2.07B |
| P/E Ratio | 12.97 |
| EPS | $0.69 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.67 |
| 52-Week Low | $7.21 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $509.86M |
| Net Income | $165.35M |
| Gross Margin | 61.27% |
3 analysts cover ADMA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.67.